| 000 | 01448 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250518003634.0 | ||
| 264 | 0 | _c20200325 | |
| 008 | 202003s 0 0 eng d | ||
| 022 | _a1879-016X | ||
| 024 | 7 |
_a10.1016/j.pharmthera.2018.10.010 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDobrian, A D | |
| 245 | 0 | 0 |
_aRole of the 12-lipoxygenase pathway in diabetes pathogenesis and complications. _h[electronic resource] |
| 260 |
_bPharmacology & therapeutics _c03 2019 |
||
| 300 |
_a100-110 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aArachidonate 12-Lipoxygenase _xmetabolism |
| 650 | 0 | 4 |
_aArachidonate 15-Lipoxygenase _xmetabolism |
| 650 | 0 | 4 |
_aDiabetes Complications _xenzymology |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 1 _xenzymology |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xenzymology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInsulin-Secreting Cells _xenzymology |
| 650 | 0 | 4 |
_aLipoxygenase Inhibitors _xpharmacology |
| 650 | 0 | 4 | _aSignal Transduction |
| 700 | 1 | _aMorris, M A | |
| 700 | 1 | _aTaylor-Fishwick, D A | |
| 700 | 1 | _aHolman, T R | |
| 700 | 1 | _aImai, Y | |
| 700 | 1 | _aMirmira, R G | |
| 700 | 1 | _aNadler, J L | |
| 773 | 0 |
_tPharmacology & therapeutics _gvol. 195 _gp. 100-110 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.pharmthera.2018.10.010 _zAvailable from publisher's website |
| 999 |
_c28964724 _d28964724 |
||